Compare FAST & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAST | EW |
|---|---|---|
| Founded | 1967 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6B | 49.5B |
| IPO Year | 1995 | 1999 |
| Metric | FAST | EW |
|---|---|---|
| Price | $45.86 | $85.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $45.75 | ★ $96.37 |
| AVG Volume (30 Days) | ★ 5.8M | 4.7M |
| Earning Date | 04-13-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.30 | ★ 0.66 |
| Revenue | ★ $8,200,500,000.00 | $6,067,600,000.00 |
| Revenue This Year | $12.81 | $13.39 |
| Revenue Next Year | $8.62 | $9.81 |
| P/E Ratio | $155.27 | ★ $132.64 |
| Revenue Growth | 8.67 | ★ 11.55 |
| 52 Week Low | $38.97 | $72.30 |
| 52 Week High | $50.63 | $89.48 |
| Indicator | FAST | EW |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 51.59 |
| Support Level | $43.20 | $81.73 |
| Resistance Level | $48.96 | $87.22 |
| Average True Range (ATR) | 0.97 | 2.41 |
| MACD | 0.26 | -0.07 |
| Stochastic Oscillator | 65.20 | 44.13 |
Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.